New study tracks Long-Term safety of DMD drug AGAMREE in boys
Disease control
Recruiting now
This study monitors the long-term safety of the drug vamorolone (AGAMREE) in boys aged 2 and older with Duchenne muscular dystrophy. Researchers will track growth, bone health, heart function, and quality of life over time. The goal is to better understand the drug's risks and be…
Sponsor: Catalyst Pharmaceuticals, Inc. • Aim: Disease control
Last updated May 15, 2026 11:55 UTC